SCHEMBL6773557

SCHEMBL6773557

Fc1ccccc1-c1nnc2cc(-c3cccs3)c(Cl)nn12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.45
HPGD P15428 2/20 0.45
HSD17B10 Q99714 2/20 0.45
USP2 O75604 1/20 0.45
LMNA P02545 1/20 0.45
HTT P42858 1/20 0.45
DCTPP1 Q9H773 2/20 0.40
SMN1; SMN2 Q16637 3/20 0.39
KDM4E B2RXH2 2/20 0.39
GABRG2 P18507 2/20 0.39
GABRB3 P28472 2/20 0.39
GABRA3 P34903 2/20 0.39
HSD11B1 P28845 1/20 0.38
LRRK2 Q5S007 3/20 0.38
RXFP1 Q9HBX9 1/20 0.38
GABRA1 P14867 1/20 0.37
GABRA5 P31644 1/20 0.37
GABRA2 P47869 1/20 0.37
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6768851 0.78 HSD11B1 (0.40) LMNAHTTDCTPP1SMN1; SMN2GABRG2
SCHEMBL6775795 0.77 DCTPP1 (0.45) ALDH1A1LMNADCTPP1GABRG2GABRB3
SCHEMBL6775681 0.77 HSD11B1 (0.43) DCTPP1GABRG2GABRB3GABRA3HSD11B1
SCHEMBL6519834 0.75 HSD11B1 (0.44) DCTPP1GABRG2GABRB3GABRA3HSD11B1
SCHEMBL6869998 0.74 HSD11B1 (0.43) DCTPP1GABRG2GABRB3GABRA3HSD11B1
SCHEMBL2656762 0.74 GABRA1 (0.54) DCTPP1GABRG2GABRB3GABRA3HSD11B1
SCHEMBL2655690 0.74 GABRG2 (0.69) GABRG2GABRB3GABRA3GABRA1GABRA5
SCHEMBL6768850 0.71 GABRA1 (0.44) HPGDLMNADCTPP1SMN1; SMN2GABRG2
SCHEMBL6524041 0.71 GABRA1 (0.47) DCTPP1GABRG2GABRB3GABRA3HSD11B1
SCHEMBL15364544 0.71 SMN1; SMN2 (0.50) ALDH1A1HPGDHSD17B10LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6828322-B2 Substituted 1,2, 4-triazolo(4,3-b)pyridazine derivatives; anxiolytic; anticonvulsant; antimigraine MERCK SHARP & DOHME LTD. 2004-12-07 US disclosed
US-20040063714-A1 Triazolo-pyridazine derivatives as ligands for GABA receptors CARLING WILLIAM ROBERT (GB) 2004-04-01 US disclosed
US-6579875-B1 Treatment of anxiety and convulsions; 7-cyclobutyl-3-(2,6-difluorophenyl)-6-(2-methyl-2H-1,2,4-triazol-3 -ylmethyoxy)-1,2,4-triazolo(4,3-b) pyridazine MERCK SHARP & DOHME LIMITED 2003-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063714-A1 Triazolo-pyridazine derivatives as ligands for GABA receptors GABRA3, GABBR1, GABRA2 ALDH1A1 1373/4885HPGD 3544/4885HSD17B10 3090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.